TY - JOUR
T1 - Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations
AU - Nakamura, Kazuhiko
AU - Chen, Chih Ken
AU - Sekine, Yoshimoto
AU - Iwata, Yasuhide
AU - Anitha, A.
AU - Loh, El Wui
AU - Takei, Nori
AU - Suzuki, Atsuko
AU - Kawai, Masayoshi
AU - Takebayashi, Kiyokazu
AU - Suzuki, Katsuaki
AU - Minabe, Yoshio
AU - Tsuchiya, Kenji
AU - Yamada, Kazuo
AU - Iyo, Masaomi
AU - Ozaki, Norio
AU - Inada, Toshiya
AU - Iwata, Nakao
AU - Harano, Mutsuo
AU - Komiyama, Tokutaro
AU - Yamada, Mitsuhiko
AU - Sora, Ichiro
AU - Ujike, Hiroshi
AU - Ball, David M.
AU - Yoshikawa, Takeo
AU - Lin, Shih Ku
AU - Mori, Norio
N1 - Funding Information:
Acknowledgments This work was supported by Grant-in-Aid for Scientific Reseach (A) from the Ministry of Education Science, Sports and Culture of Japan and grant from Stanley Foundation. Recruitment of Taiwanese sample was supported by research grants from the Chang Gung Memorial Hospital, Taiwan and the National Science Council, Taiwan. We thank Osada Naoko and Kamahori Naomi for technical assistance.
PY - 2006/9
Y1 - 2006/9
N2 - SOD2 (superoxide dismutase 2) plays a crucial role in protecting the cells against damage caused by free radicals, by catalyzing their detoxification. On the other hand, cell damage caused by free radical generation following methamphetamine administration has been postulated as one of the possible pathophysiological mechanisms for methamphetamine psychosis. Hence, we investigated the association of SOD2 polymorphisms with the development of methamphetamine psychosis, in two independent populations of Japan and Taiwan. We recruited 116 patients with methamphetamine psychosis and 189 controls in Japan, and 135 patients with methamphetamine psychosis and 204 controls in Taiwan. The methamphetamine group was divided into two clinical subtypes: a transient type of psychosis (i.e., good prognosis) and a prolonged type of psychosis (i.e., poor prognosis), according to the course of the manifestation of psychosis. With reference to the genotypic and allelic frequencies of Ala/Val functional polymorphism in exon 2, we found significant differences between individuals with prolonged methamphetamine psychosis and control samples from Japan and Taiwan in the genotypic (P value 0.014 and 0.016, respectively) and in the allelic (P value 0.004 and 0.047, respectively) frequencies. Our results suggest that Ala/Val polymorphism of the SOD2 gene could be associated with the risk of developing methamphetamine psychosis.
AB - SOD2 (superoxide dismutase 2) plays a crucial role in protecting the cells against damage caused by free radicals, by catalyzing their detoxification. On the other hand, cell damage caused by free radical generation following methamphetamine administration has been postulated as one of the possible pathophysiological mechanisms for methamphetamine psychosis. Hence, we investigated the association of SOD2 polymorphisms with the development of methamphetamine psychosis, in two independent populations of Japan and Taiwan. We recruited 116 patients with methamphetamine psychosis and 189 controls in Japan, and 135 patients with methamphetamine psychosis and 204 controls in Taiwan. The methamphetamine group was divided into two clinical subtypes: a transient type of psychosis (i.e., good prognosis) and a prolonged type of psychosis (i.e., poor prognosis), according to the course of the manifestation of psychosis. With reference to the genotypic and allelic frequencies of Ala/Val functional polymorphism in exon 2, we found significant differences between individuals with prolonged methamphetamine psychosis and control samples from Japan and Taiwan in the genotypic (P value 0.014 and 0.016, respectively) and in the allelic (P value 0.004 and 0.047, respectively) frequencies. Our results suggest that Ala/Val polymorphism of the SOD2 gene could be associated with the risk of developing methamphetamine psychosis.
UR - http://www.scopus.com/inward/record.url?scp=33746995982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746995982&partnerID=8YFLogxK
U2 - 10.1007/s00439-006-0189-y
DO - 10.1007/s00439-006-0189-y
M3 - Article
C2 - 16807759
AN - SCOPUS:33746995982
SN - 0340-6717
VL - 120
SP - 243
EP - 252
JO - Human Genetics
JF - Human Genetics
IS - 2
ER -